EIF3E
EIF3E (Eukaryotic translation initiation factor 3 subunit E) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Cervical cancer, Breast cancer and Lung cancer.
Overview
Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is required for several steps in the initiation of protein synthesis. The eIF-3 complex associates with the 40S ribosome and facilitates the recruitment of eIF-1, eIF-1A, eIF-2:GTP:methionyl-tRNAi and eIF-5 to form the 43S pre-initiation complex (43S PIC). The eIF-3 complex stimulates mRNA recruitment to the 43S PIC and scanning of the mRNA for AUG recognition.
Open Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 0.92, genetic association 0.17, somatic mutation 0.81). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Cervical Squamous Cell Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · EIF3E (Eukaryotic translation initiation factor 3 subunit E) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Cervical cancer, Breast cancer and Lung cancer.
- 1 · What it is
EIF3E (Eukaryotic translation initiation factor 3 subunit E) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Cervical cancer, Breast cancer and Lung cancer.
- 2 · What goes wrong in cancer
Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is required for several steps in the initiation of protein synthesis.
- 3 · How drugs use it
No product in this corpus aims at EIF3E yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:3277 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P60228 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000104408 (association with cancer (MONDO_0004992) 0.64; per-cancer scores at or above 0.5: breast cancer 0.53, lung cancer 0.51 (GraphQL API, CC0)); IntOGen EIF3E (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is required for several steps in the initiation of protein synthesis. The eIF-3 complex associates with the 40S ribosome and facilitates the recruitment of eIF-1, eIF-1A, eIF-2:GTP:methionyl-tRNAi and eIF-5 to form the 43S pre-initiation complex (43S PIC). The eIF-3 complex stimulates mRNA recruitment to the 43S PIC and scanning of the mRNA for AUG recognition. The eIF-3 complex is also required for disassembly and recycling of post-termination ribosomal complexes and subsequently prevents premature joining of the 40S and 60S ribosomal subunits prior to initiation. The eIF-3 complex specifically targets and initiates translation of a subset of mRNAs involved in cell proliferation, including cell cycling, differentiation and apoptosis, and uses different modes of RNA stem-loop binding to exert either translational activation or repression. Required for nonsense-mediated mRNA decay (NMD); may act in conjunction with UPF2 to divert mRNAs from translation to the NMD pathway. Location: Cytoplasm; Nucleus, PML body (UniProt). Locus 8q23.1 (HGNC).
- Cervical cancer: IntOGen driver in 1 cohort (CESC)
- Breast cancer: Open Targets association 0.53 with breast cancer (MONDO_0007254)
- Lung cancer: Open Targets association 0.51 with lung cancer (MONDO_0008903)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"EIF3E" OR ABSTRACT:"EIF3E" OR TITLE:"eukaryotic translation initiation factor 3 subunit E" OR ABSTRACT:"eukaryotic translation initiation factor 3 subunit E" OR TITLE:"Eukaryotic translation initiation factor 3 subunit E" OR ABSTRACT:"Eukaryotic translation initiation factor 3 subunit E" OR TITLE:"eIF3-p48" OR ABSTRACT:"eIF3-p48" OR TITLE:"INT6" OR ABSTRACT:"INT6" OR TITLE:"EIF3S6" OR ABSTRACT:"EIF3S6") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about EIF3E, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetSND1
Shares Lung cancer (all types), Cervical cancer, Breast cancer (all types), IntOGen.
- TargetCDC73
Shares Lung cancer (all types), Breast cancer (all types), IntOGen, Open Targets Platform.
- TargetTRIM33
Shares Lung cancer (all types), Breast cancer (all types), IntOGen, Open Targets Platform.
- TargetRSPO3
Shares Lung cancer (all types), Breast cancer (all types), Open Targets Platform.
- TargetAFDN
Shares Lung cancer (all types), Breast cancer (all types), IntOGen, Open Targets Platform.
- TargetATP2B3
Shares Lung cancer (all types), Breast cancer (all types), IntOGen, Open Targets Platform.
- TargetFCRL4
Shares Lung cancer (all types), Breast cancer (all types), IntOGen, Open Targets Platform.
- TargetCLTCL1
Shares Lung cancer (all types), Breast cancer (all types), IntOGen, Open Targets Platform.